Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)

Acrivon Therapeutics (NASDAQ:ACRV) and Oasmia Pharmaceutical (OTCMKTS:OASMY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares Acrivon Therapeutics and Oasmia Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90 million	($2.02)	-0.69
Oasmia Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Institutional and Insider Ownership

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Acrivon Therapeutics and Oasmia Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1	1	4	0	2.50
Oasmia Pharmaceutical	0	0	0	0	0.00

Acrivon Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 739.33%. Given Acrivon Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Oasmia Pharmaceutical.

Volatility & Risk

Acrivon Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical has a beta of 33.35, indicating that its stock price is 3,235% more volatile than the S&P 500.

Profitability

This table compares Acrivon Therapeutics and Oasmia Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-57.23%	-51.09%
Oasmia Pharmaceutical	N/A	N/A	N/A

Summary

Acrivon Therapeutics beats Oasmia Pharmaceutical on 5 of the 8 factors compared between the two stocks.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

About Oasmia Pharmaceutical

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.